Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 5/20 | 0.41 |
| ▸ | CA6 | P23280 | 5/20 | 0.41 |
| ▸ | CA7 | P43166 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 5/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA4 | P22748 | 4/20 | 0.41 |
| ▸ | CA5A | P35218 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CA3 | P07451 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9771596 | 0.96 | KDM4E (0.44) | CASP2TSHRTDP1ALDH1A1CA12 | |
| SCHEMBL2000125 | 0.96 | — | — | |
| SCHEMBL3207850 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL7038936 | 0.86 | — | — | |
| SCHEMBL25154093 | 0.85 | TSHR (0.55) | CASP2TSHRTDP1ALDH1A1CA12 | |
| SCHEMBL22505071 | 0.83 | — | — | |
| SCHEMBL2709324 | 0.81 | — | — | |
| SCHEMBL22566437 | 0.81 | — | — | |
| SCHEMBL274740 | 0.81 | — | — | |
| SCHEMBL14871705 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116211887-A | Composition for treating acid-base imbalance | 特里赛达公司 | 2023-06-06 | — | — | CN | claimed |
| US-11197887-B2 | Proton-binding polymers for oral administration | TRICIDA, INC. (US) | 2021-12-14 | — | — | US | claimed |
| US-20210205351-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | RENIBUS THERAPEUTICS, INC. | 2021-07-08 | — | — | US | claimed |
| EP-3831395-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | Tricida Inc. (US) | 2021-06-09 | — | — | EP | claimed |
| EP-3593808-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | TRICIDA INC (US) | 2020-12-09 | — | — | EP | claimed |
| EP-3578185-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | TRICIDA INC (US) | 2020-08-05 | — | — | EP | claimed |
| EP-3229816-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | TRICIDA INC (US) | 2020-02-05 | — | — | EP | claimed |
| US-20190209607-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | TRICIDA, INC. | 2019-07-11 | — | — | US | claimed |
| EP-3287133-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | TRICIDA INC (US) | 2019-04-17 | — | — | EP | claimed |
| EP-3287133-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | Tricida Inc. (US) | 2018-02-28 | — | — | EP | claimed |
| EP-3812761-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | RENOSIS INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250222021-A1 | METHOD OF TREATING ACID-BASE DISORDERS | RENIBUS THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250025494-A1 | COMPOSITIONS FOR AND METHOD OF TREATING ACID-BASE DISORDERS | RENIBUS THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-20250009785-A1 | HCL-BINDING COMPOSITIONS FOR AND METHODS OF TREATING ACID-BASE DISORDERS | RENIBUS THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-11992501-B2 | Compositions for and methods of treating acid-base disorders | RENOSIS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2017193050-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | TRICIDA, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| EP-3003327-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | TRICIDA INC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-20160074430-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | RENIBUS THERAPEUTICS, INC. | 2016-03-17 | — | — | US | disclosed |
| US-9205107-B2 | Proton-binding polymers for oral administration | TRICIDA, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150056451-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | RENIBUS THERAPEUTICS, INC. | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11992501-B2 | Compositions for and methods of treating acid-base disorders | SLC10A2, SLC10A1, SLC26A3 | CASP2 4329/4885TSHR 2197/4885TDP1 2675/4885 |
| US-20150056451-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | SLC9A1, HRH2, SLC9A2 | CASP2 4532/4885TSHR 1639/4885TDP1 3385/4885 |
| US-20250222021-A1 | METHOD OF TREATING ACID-BASE DISORDERS | SLC10A2, SLC10A1, SI | CASP2 4108/4885TSHR 1626/4885TDP1 2189/4885 |
| US-20160074430-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | SLC9A1, HRH2, SLC9A2 | CASP2 4532/4885TSHR 1639/4885TDP1 3385/4885 |
| US-20250009785-A1 | HCL-BINDING COMPOSITIONS FOR AND METHODS OF TREATING ACID-BASE DISORDERS | SLC10A2, SLC10A1, SLC7A1 | CASP2 4634/4885TSHR 1667/4885TDP1 2827/4885 |
| US-20210205351-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | SLC10A2, SLC10A1, SLC26A3 | CASP2 4421/4885TSHR 2261/4885TDP1 2434/4885 |
| US-20250025494-A1 | COMPOSITIONS FOR AND METHOD OF TREATING ACID-BASE DISORDERS | SLC10A2, SLC10A1, GLS | CASP2 2885/4885TSHR 3346/4885TDP1 1606/4885 |
| US-20190209607-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | SLC10A2, SLC10A1, SLC26A3 | CASP2 4421/4885TSHR 2261/4885TDP1 2434/4885 |
| US-11197887-B2 | Proton-binding polymers for oral administration | SLC9A1, HRH2, SLC9A2 | CASP2 4532/4885TSHR 1639/4885TDP1 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.